S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
NASDAQ:ATXI

Avenue Therapeutics Stock Competitors

$1.26
-0.01 (-0.79 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.25
$1.29
50-Day Range
$1.26
$1.83
52-Week Range
$1.25
$7.69
Volume71,439 shs
Average Volume232,857 shs
Market Capitalization$21.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69

Avenue Therapeutics (NASDAQ:ATXI) Vs. BPTS, AADI, AGRX, GANX, AKTX, MITO, DMAC, ELDN, ARAV, and ADIL

Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Biophytis (BPTS), Aadi Bioscience (AADI), Agile Therapeutics (AGRX), Gain Therapeutics (GANX), Akari Therapeutics (AKTX), Stealth BioTherapeutics (MITO), DiaMedica Therapeutics (DMAC), Eledon Pharmaceuticals (ELDN), Aravive (ARAV), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical preparations" industry.

Avenue Therapeutics vs.

Avenue Therapeutics (NASDAQ:ATXI) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.

Avenue Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 376.19%. Aadi Bioscience has a consensus price target of $47.67, indicating a potential upside of 81.73%. Given Avenue Therapeutics' higher probable upside, equities research analysts clearly believe Avenue Therapeutics is more favorable than Aadi Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aadi Bioscience has higher revenue and earnings than Avenue Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$5.15 millionN/AN/A
Aadi Bioscience$15 million5.56-$4.32 million-$1.50-17.49

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Aadi Bioscience's average media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
Aadi Bioscience Neutral

Avenue Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Avenue Therapeutics received 140 more outperform votes than Aadi Bioscience when rated by MarketBeat users. However, 100.00% of users gave Aadi Bioscience an outperform vote while only 60.00% of users gave Avenue Therapeutics an outperform vote.

CompanyUnderperformOutperform
Avenue TherapeuticsOutperform Votes
144
60.00%
Underperform Votes
96
40.00%
Aadi BioscienceOutperform Votes
4
100.00%
Underperform Votes
No Votes

Aadi Bioscience's return on equity of -42.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue Therapeutics N/A -205.86% -147.89%
Aadi Bioscience N/A -42.00% -39.88%

6.7% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 51.9% of Aadi Bioscience shares are owned by institutional investors. 4.0% of Avenue Therapeutics shares are owned by insiders. Comparatively, 7.1% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Aadi Bioscience beats Avenue Therapeutics on 10 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Avenue Therapeutics (NASDAQ:ATXI) vs. Its Competitors

TypeAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
P/E Ratio-2.2123.9032.4327.86

Avenue Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTS
Biophytis
0 of 5 stars
$6.93
-0.0%
N/AN/A$83.68MN/A0.002,020
AADI
Aadi Bioscience
1.8667 of 5 stars
$26.23
-3.7%
$48.00
-83.0%
N/A$83.39M$15M-4.3712Gap Down
AGRX
Agile Therapeutics
2.1583 of 5 stars
$0.89
-14.7%
$3.63
-309.5%
-71.2%$82.50M$750,000.00-1.1428Positive News
Gap Up
High Trading Volume
GANX
Gain Therapeutics
1.6781 of 5 stars
$6.75
-2.8%
$30.00
-344.4%
N/A$80.17M$30,000.000.0016Positive News
AKTX
Akari Therapeutics
1.2664 of 5 stars
$1.68
-1.8%
N/A-4.6%$79.89MN/A-2.752,020Short Interest ↓
MITO
Stealth BioTherapeutics
1.5531 of 5 stars
$1.38
-2.2%
$3.00
-117.4%
-2.8%$79.47M$21.09M-3.292,020Short Interest ↑
DMAC
DiaMedica Therapeutics
1.8598 of 5 stars
$4.19
-2.1%
$21.00
-401.2%
-8.9%$78.71M$500,000.00-5.3711Positive News
ELDN
Eledon Pharmaceuticals
2.4698 of 5 stars
$5.50
-2.4%
$29.00
-427.3%
N/A$78.69MN/A-0.5110
ARAV
Aravive
1.9398 of 5 stars
$3.76
-2.1%
$23.33
-520.6%
-25.8%$77.89M$5.68M-2.2117Short Interest ↓
News Coverage
ADIL
Adial Pharmaceuticals
1.9315 of 5 stars
$3.79
-2.4%
$11.00
-190.2%
+101.6%$76.93MN/A-3.682,018
LUMO
Lumos Pharma
2.325 of 5 stars
$9.18
-0.8%
$28.60
-211.5%
-35.5%$76.72M$170,000.00-4.2129
MBRX
Moleculin Biotech
0.9331 of 5 stars
$2.68
-1.1%
N/A-45.4%$76.52MN/A-1.5213News Coverage
Gap Up
ONTX
Onconova Therapeutics
2.0581 of 5 stars
$3.67
-0.0%
$11.50
-213.4%
-15.7%$76.27M$230,000.00-2.5012
GRAY
Graybug Vision
2.2726 of 5 stars
$3.56
-0.6%
$17.29
-385.6%
-76.9%$75.78MN/A-0.6831Analyst Downgrade
ONCS
OncoSec Medical
1.9581 of 5 stars
$1.91
-7.9%
$11.00
-475.9%
-52.3%$74.84MN/A-1.4044Analyst Report
AEZS
Aeterna Zentaris
0.9864 of 5 stars
$0.61
-0.0%
N/A+63.5%$73.40M$3.65M-7.5611
LGVN
Longeveron
0.3333 of 5 stars
$3.82
-4.2%
N/AN/A$73.02M$5.63M0.0012Gap Up
ZSAN
Zosano Pharma
1.8114 of 5 stars
$0.62
-1.6%
$2.17
-247.8%
-7.0%$72.01M$220,000.00-1.8945Gap Down
APVO
Aptevo Therapeutics
2.0798 of 5 stars
$14.64
-2.4%
$50.00
-241.5%
+109.7%$71.65M$4.31M0.0058
CYAD
Celyad Oncology
1.6814 of 5 stars
$4.59
-3.5%
$15.00
-227.2%
-44.0%$71.04M$10,000.00-3.2883High Trading Volume
ADXS
Advaxis
1.5531 of 5 stars
$0.49
-4.1%
$2.25
-362.0%
+20.1%$70.93M$250,000.00-2.5618Short Interest ↓
AYTU
Aytu Biopharma
1.8564 of 5 stars
$2.54
-4.3%
$12.75
-402.0%
+146.6%$69.98M$65.63M-0.7675
OCUP
Ocuphire Pharma
2.2048 of 5 stars
$4.12
-4.1%
$21.75
-427.9%
N/A$69.62MN/A-0.785Short Interest ↑
SNPX
Synaptogenix
0 of 5 stars
$11.31
-5.6%
N/AN/A$69.40MN/A0.004Short Interest ↑
CEMI
Chembio Diagnostics
1.5298 of 5 stars
$2.41
-0.0%
$9.00
-273.4%
-50.3%$68.98M$32.47M-1.85355Short Interest ↑
GLMD
Galmed Pharmaceuticals
1.825 of 5 stars
$2.74
-0.4%
$21.00
-666.4%
-14.9%$68.73M$2.04M-1.8121
ADXN
Addex Therapeutics
1.6515 of 5 stars
$8.16
-4.3%
$28.00
-243.1%
-33.1%$67.01M$4.14M-3.1327Gap Down
MACK
Merrimack Pharmaceuticals
1.4598 of 5 stars
$4.77
-6.7%
N/A+22.8%$63.90MN/A-17.6527
MNPR
Monopar Therapeutics
2.0333 of 5 stars
$4.95
-0.8%
$49.00
-889.9%
-0.2%$62.29MN/A-6.2710News Coverage
Gap Down
ASLN
ASLAN Pharmaceuticals
1.8531 of 5 stars
$1.59
-1.9%
$8.00
-403.1%
-22.4%$60.41M$3M-4.182,020
CWBR
CohBar
2.3667 of 5 stars
$0.93
-3.2%
$5.13
-450.6%
-4.9%$59.95MN/A-3.2112
VCNX
Vaccinex
1.1331 of 5 stars
$1.94
-4.1%
N/A-2.0%$59.75M$630,000.000.0040Short Interest ↓
ENSC
Ensysce Biosciences
0.3333 of 5 stars
$2.42
-2.1%
N/AN/A$58.75MN/A0.004
VYNE
VYNE Therapeutics
2.0314 of 5 stars
$1.14
-7.0%
$8.50
-645.6%
-85.5%$58.72M$20.99M-0.58106Short Interest ↓
LMNL
Liminal BioSciences
1.3215 of 5 stars
$1.95
-0.5%
$7.75
-297.4%
-73.5%$58.39M$2.48M-0.60251Short Interest ↓
News Coverage
RZLT
Rezolute
2.4917 of 5 stars
$6.66
-0.2%
$25.40
-281.4%
-64.9%$57.41MN/A-2.4523High Trading Volume
CLRB
Cellectar Biosciences
1.6331 of 5 stars
$0.91
-1.1%
$4.25
-367.1%
-26.0%$55.60MN/A-1.9811
NERV
Minerva Neurosciences
2.1098 of 5 stars
$1.30
-4.6%
$6.50
-401.9%
-61.0%$55.33M$41.18M-1.5811
VRPX
Virpax Pharmaceuticals
0 of 5 stars
$4.65
-3.7%
N/AN/A$54.48MN/A0.002
RMTI
Rockwell Medical
1.7048 of 5 stars
$0.57
-7.1%
$5.00
-785.0%
-48.6%$53.05M$62.20M-1.57300Short Interest ↓
Positive News
HUGE
FSD Pharma
0.125 of 5 stars
$1.42
-0.7%
N/A-33.6%$50.89M$190,000.00-0.709Positive News
CYCC
Cyclacel Pharmaceuticals
1.7198 of 5 stars
$5.36
-3.9%
$17.00
-217.2%
+37.8%$49.49M$150,000.00-1.872,018
RNXT
RenovoRx
1.7 of 5 stars
$5.88
-1.7%
$15.00
-155.1%
N/A$49.30MN/A0.002,021
ACXP
Acurx Pharmaceuticals
0 of 5 stars
$4.81
-2.1%
N/AN/A$48.67MN/A0.003
RVPH
Reviva Pharmaceuticals
2.1583 of 5 stars
$3.63
-3.3%
$10.00
-175.5%
N/A$48.60MN/A-2.905Upcoming Earnings
Short Interest ↓
Positive News
DFFN
Diffusion Pharmaceuticals
1.0048 of 5 stars
$0.47
-0.0%
N/A-43.7%$48.39MN/A-2.0614Short Interest ↓
Gap Down
ASRT
Assertio
1.1298 of 5 stars
$1.01
-1.0%
N/A+39.4%$44.94M$106.28M-0.7427Short Interest ↓
ACST
Acasti Pharma
1.0581 of 5 stars
$1.71
-1.8%
N/A+5.2%$44.55M$200,000.00-1.9432Short Interest ↑
FWP
Forward Pharma A/S
1.0848 of 5 stars
$6.42
-2.8%
N/A-1.4%$44.25MN/A0.002,020Gap Down
NRBO
NeuroBo Pharmaceuticals
2.0333 of 5 stars
$1.92
-1.0%
$16.00
-733.3%
-70.8%$42.79MN/A-1.127
This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.